John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Roe, M. T., K. W. Mahaffey, R. Kilaru, J. H. Alexander, K. M. Akkerhuis, M. L. Simoons, R. A. Harrington, et al. “Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes..” Eur Heart J 25, no. 4 (February 2004): 313–21. https://doi.org/10.1016/j.ehj.2003.12.009.

PMID
14984920
Full Text

Alexander, J. H., C. K. Dyke, H. Yang, R. C. Becker, V. Hasselblad, L. A. Zillman, N. S. Kleiman, et al. “Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot..” J Thromb Haemost 2, no. 2 (February 2004): 234–41.

PMID
14995984
Scholars@Duke

Rebeiz, Abdallah G., Matthew T. Roe, John H. Alexander, Kenneth W. Mahaffey, Christopher B. Granger, Eric D. Peterson, Robert M. Califf, and Robert A. Harrington. “Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes..” Am J Med 116, no. 2 (January 15, 2004): 119–29.

PMID
14715326
Scholars@Duke

Alexander, John H., Robert A. Harrington, Manju Bhapkar, Kenneth W. Mahaffey, A Michael Lincoff, E Magnus Ohman, Peter Klootwijk, et al. “Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes..” Am J Med 115, no. 8 (December 1, 2003): 613–19.

PMID
14656613
Scholars@Duke

Alexander, John H., and Manesh R. Patel. “Screening for structural heart disease: time to stop listening and start looking..” American Heart Journal 146, no. 4 (October 2003): 570–71. https://doi.org/10.1016/s0002-8703(03)00397-1.

PMID
14564308
Full Text

Sinnaeve, Peter, John Alexander, Ann Belmans, Kris Bogaerts, Anatoli Langer, Rafaël Diaz, Diego Ardissino, et al. “One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction..” Am Heart J 146, no. 1 (July 2003): 27–32. https://doi.org/10.1016/S0002-8703(03)00117-0.

PMID
12851604
Full Text

Serebruany, Victor L., Alex I. Malinin, Kevin P. Callahan, Azan Binbrek, Frans Van De Werf, John H. Alexander, Christopher B. Granger, Paul A. Gurbel, and Paul A. Assessment of the Safety and Efficacy of a New Thrombolytic Agent platelet substudy. “Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy..” Am Heart J 145, no. 4 (April 2003): 636–42. https://doi.org/10.1067/mhj.2003.210.

PMID
12679759
Full Text

Akkerhuis, K Martijn, John H. Alexander, Barbara E. Tardiff, Eric Boersma, Robert A. Harrington, A Michael Lincoff, and Maarten L. Simoons. “Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?.” Circulation 105, no. 5 (February 5, 2002): 554–56.

PMID
11827918
Scholars@Duke

Callahan, K. P., A. I. Malinin, P. A. Gurbel, J. H. Alexander, C. B. Granger, D. Atar, and V. L. Serebruany. “Platelets and thrombolysis: Cooperation or contrariety?.” Heartdrug 1, no. 5 (December 1, 2001): 281–90. https://doi.org/10.1159/000048975.

Full Text

Pages